Company Analysis
Sign in

Compass Therapeutics, Inc. (CMPX)

Nasdaq: CMPX · Biological Products, (No Diagnostic Substances) · Boston, MA · filing with the SEC since 2018
Full chart Alerts Compare
Grade4.7
◀ Past 4.0● Present 5.5▶ Future 4.4
4 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

114 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Compass Therapeutics, Inc.’s names, not what it holds today.

Patents granted
114
112 utility, 1 design, 1 reissue, 1976 to Dec 31, 2025
Granted in 2025
5
Against 2 in 2024 and 6 in 2023
Applications published
81
1 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals28
Biotechnology4
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Compass Therapeutics, LLC its own name
US, as the owner printed on each patent. 7 more under the same name are not counted (printed in CN, printed in CA, printed in KR)
114 granted
60 published
Compass Therapeutics LLC its own name
named as the applicant on its applications, in US
0 granted
21 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 23, 202512,503,511Multispecific binding constructs against checkpoint molecules and uses thereofPharmaceuticalsCompass Therapeutics, LLC
Nov 11, 202512,467,062Transgenic mouse expressing common human light chainBiotechnologyCompass Therapeutics, LLC
Nov 4, 202512,460,004Antibodies that bind CD277 and uses thereofPharmaceuticalsCompass Therapeutics, LLC
Apr 29, 202512,286,483Method of treating cancer using CD137 antibodies and PD-1 antagonistsBiotechnologyCompass Therapeutics, LLC
Jan 7, 202512,186,285Compositions and methods of treatment for tinea pedisPharmaceuticalsCompass Therapeutics, LLC
Apr 30, 202411,970,538Multispecific binding constructs against checkpoint molecules and uses thereofPharmaceuticalsCompass Therapeutics, LLC
Jan 9, 202411,865,179Progesterone formulations having a desirable PK profilePharmaceuticalsCompass Therapeutics, LLC
Dec 26, 202311,851,497CD137 antibodies and tumor antigen-targeting antibodies and uses thereofBiotechnologyCompass Therapeutics, LLC
Oct 24, 202311,793,819Natural combination hormone replacement formulations and therapiesPharmaceuticalsCompass Therapeutics, LLC
Sep 12, 202311,752,207Agonist antibodies that bind human CD137 and uses thereofPharmaceuticalsCompass Therapeutics, LLC
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Oct 9, 20252025/0313645CD137 ANTIBODIES AND PD-1 ANTAGONISTS AND USES THEREOFBiotechnologyCompass Therapeutics, LLC
Oct 31, 20242024/0358839PROGESTERONE FORMULATIONS HAVING A DESIRABLE PK PROFILEPharmaceuticalsCompass Therapeutics, LLC
Oct 24, 20242024/0350514VAGINAL INSERTED ESTRADIOL PHARMACEUTICAL COMPOSITIONS AND METHODSPharmaceuticalsCompass Therapeutics, LLC
Aug 8, 20242024/0262914MULTISPECIFIC BINDING CONSTRUCTS AGAINST CHECKPOINT MOLECULES AND USES THEREOFPharmaceuticalsCompass Therapeutics LLC · patent 12,503,511 granted from it
Jun 6, 20242024/0181050AGONIST ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOFPharmaceuticalsCompass Therapeutics LLC
Apr 11, 20242024/0115584NATURAL COMBINATION HORMONE REPLACEMENT FORMULATIONS AND THERAPIESPharmaceuticalsCompass Therapeutics, LLC
Jan 4, 20242024/0002525CD137 ANTIBODIES AND PD-1 ANTAGONISTS AND USES THEREOFBiotechnologyCompass Therapeutics, LLC · patent 12,286,483 granted from it
Jul 6, 20232023/0210765VAGINAL INSERTED ESTRADIOL PHARMACEUTICAL COMPOSITIONS AND METHODSPharmaceuticalsCompass Therapeutics, LLC
Mar 2, 20232023/0062295VAGINAL INSERTED ESTRADIOL PHARMACEUTICAL COMPOSITIONS AND METHODSPharmaceuticalsCompass Therapeutics, LLC
Apr 14, 20222022/0111047FORMULATIONS OF ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOFPharmaceuticalsCompass Therapeutics LLC
What it applied for, 2024 to 2025: Pharmaceuticals 5 · Biotechnology 2.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton CMPX · research, not advice